Successful Treatment of a Severe Vision-Threatening Paradoxical Tuberculous Reaction with Infliximab: First Pediatric Use.

Autor: Abo YN; From the Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Victoria, Australia., Curtis N; From the Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Victoria, Australia., Butters C; From the Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Victoria, Australia., Rozen TH; From the Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Victoria, Australia.; Department of Paediatrics, The University of Melbourne, Victoria, Australia.; Infectious Diseases Group, Murdoch Children's Research Institute, Victoria, Australia., Marais BJ; Infectious Diseases Unit, The Children's Hospital at Westmead, New South Wales, Australia.; University of Sydney, New South Wales, Australia., Gwee A; From the Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Victoria, Australia.; Department of Paediatrics, The University of Melbourne, Victoria, Australia.; Infectious Diseases Group, Murdoch Children's Research Institute, Victoria, Australia.
Jazyk: angličtina
Zdroj: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2020 Apr; Vol. 39 (4), pp. e42-e45.
DOI: 10.1097/INF.0000000000002578
Abstrakt: A 7-year-old girl with tuberculous (TB) meningitis developed optochiasmatic arachnoiditis, a vision-threatening paradoxical reaction, after starting TB treatment including adjunctive steroid therapy. She was treated with infliximab with complete recovery. This is the first report of the use of a tissue necrosis factor α inhibitor for the treatment of a severe paradoxical TB reaction in a child.
Databáze: MEDLINE